(Circulation. 2000;102:351.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Improvement of Endothelial Function by Chronic Angiotensin-Converting Enzyme Inhibition in Heart Failure
Role of Nitric Oxide, Prostanoids, Oxidant Stress, and Bradykinin
From the Department of Pharmacology, Institut National de la Sante et de la Recherche Medicale, INSERM Egg20, Institut Federatif de Recherche Multidisciplinaires sur les Peptides, 23, Rouen University Medical School, Rouen, France.
Correspondence to Prof C. Thuillez, MD, PhD, Service de Pharmacologie, CHU de Rouen, 76031 Rouen, Cedex, France. E-mail Christian.Thuilllez{at}chu-rouen.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Chronic heart failure (CHF) impairs the endothelium-dependent, flow-mediated dilation (FMD) of small arteries. However, whether chronic angiotensin-converting enzyme (ACE) inhibition affects the impairment of FMD in CHF is unknown. We investigated the effects of long-term ACE inhibition on the FMD of peripheral arteries in rats with CHF and the mechanism(s) involved.
Methods and Results—FMD was assessed in isolated, perfused gracilis muscle arteries from sham-operated, and untreated or ACE inhibitor-treated (perindopril 2 mg · kg-1 · day-1 for 10 weeks) rats with CHF (coronary artery ligation). The role of nitric oxide (NO), prostaglandins, and free radicals was assessed by pretreating the vessels with the NO synthase inhibitor NW-nitro-L-arginine, the cyclooxygenase inhibitor diclofenac, or the free radical scavenger N-2-mercaptopropionyl-glycine (MPG). Endothelial NO synthase mRNA expression was determined by reverse transcriptase polymerase chain reaction. In animals with hemodynamic and echographic signs of CHF, FMD was converted into vasoconstriction, and this was prevented by ACE inhibition. FMD of arteries from sham-operated or ACE inhibitor–treated CHF rats was abolished by NW-nitro-L-arginine. In untreated CHF rats, FMD was increased by diclofenac and MPG. In contrast, in arteries from ACE inhibitor–treated rats, neither diclofenac nor MPG affected FMD. In parallel, ACE inhibition prevented the reduction of endothelial NO synthase mRNA by CHF.
Conclusions—In CHF, ACE inhibition normalized NO-dependent dilatation and suppressed the production of vasoconstrictor prostanoid(s), resulting in improved FMD. The improvement of FMD might contribute to the beneficial effects of ACE inhibition during CHF.
Key Words: angiotensin-converting enzyme inhibitors • dilatation • heart failure • muscle, skeletal • prostaglandins • nitric oxide synthase • oxidative stress
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
One of the main consequences of chronic heart failure (CHF) is abnormal peripheral arterial resistance,1 both at rest and after exercise. The vascular endothelium is involved in this modification of vasomotor tone through the release of vasoactive substances such as nitric oxide (NO), prostaglandins, endothelin, or superoxide anions. Indeed, the endothelium-dependent responses to acetylcholine are impaired in humans with CHF2 and in experimental models of CHF.3 4 5 Recent clinical studies have documented an impaired endothelium-dependent flow-mediated dilation (FMD) of conduit arteries in human CHF.6 More recently, we have shown that CHF abolishes the FMD of small muscular arteries, but it only moderately impairs the response to acetylcholine,7 suggesting that the response to flow is a more sensitive marker of endothelial dysfunction than the response to acetylcholine. Such an impaired response may be caused by a decrease in eNOS mRNA expression, resulting in reduced NO synthesis. Alternatively, this impaired FMD may be due in part to an increased production of vasoconstrictors, such as prostanoids, or an increased production of oxygen-derived free radicals.8
Angiotensin-converting enzyme (ACE) inhibitors have beneficial effects on ventricular enlargement9 and survival in CHF.10 This is related, in part, to the reduction in peripheral resistance they induce. Although ACE inhibitors normalize the dilator response to acetylcholine in CHF,5 it is unknown whether they prevent the impaired FMD seen in CHF, an effect that could contribute to the reduction in peripheral resistance. The present experiments were designed to investigate, in a rat model of CHF, the effect of long-term ACE inhibition with perindopril on the CHF-induced impairment of FMD and to assess the role of NO, prostaglandins, oxidative stress, and bradykinin in these effects.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals and Treatment
Myocardial infarction was produced in 11-week-old male Wistar rats (Charles River, Saint Aubin Les Elbeuf, France) by left coronary artery ligation using the method of Pfeffer et al,11 as modified in our laboratory.12 With this method, the 24-hour mortality rate was
22%. Seven days after
ligation, rats with CHF were randomized into the following 2 groups:
untreated or ACE inhibitor–treated (perindopril 2 mg
· kg-1 · day-1
in drinking water).5 Sham-operated rats were also
evaluated.
Hemodynamic Parameters Assessed in
Anesthetized Rats
After 10 weeks, rats were anesthetized with
pentobarbital (50 mg/kg IP). The right carotid artery and the right
external jugular vein were cannulated with a
micromanometer-tipped catheter (SPR 407, Millar
Instruments) and advanced into the aorta and thoracic vena cava,
respectively, to record arterial pressure and central
venous pressure (CVP). The aortic catheter was then advanced into the
left ventricle (LV) to record LV pressure and its maximal rate of
rise (dP/dtmax).
Echocardiographic Studies
Transthoracic Doppler
echocardiographic studies were performed after 10 weeks
of treatment in rats anesthetized with methohexital (50 mg/kg
IP) using an echocardiographic system equipped with a
7-MHz transducer (Acuson 128 XP/10C), as previously
described.12
In Vitro Vascular Studies
After assessment of the hemodynamic
parameters, an artery of the gracilis muscle was carefully
isolated under a dissection microscope and transferred to an
arteriograph.7 13 Arteries were preconstricted by the
addition of phenylephrine, after which cumulative
concentrations of acetylcholine (10-9 to
10-4 mol/L) were added under zero-flow
conditions. The vessels were then washed and again preconstricted with
phenylephrine; basal FMD was then assessed. For this
purpose, perfusate flow rate was increased from 0 to 370
µL/min in a stepwise manner.
Four series of experiments were performed on arteries obtained from different rats; in these experiments, the role of NO, prostaglandins, free radicals, and bradykinin were assessed using the NO synthase inhibitor NW-nitro-L-arginine (L-NA; 10-5 mol/L), the cyclooxygenase inhibitor diclofenac (10-5 mol/L), the free radical scavenger N-2-mercaptopropionyl-glycine (MPG; 10-5 mol/L), and the bradykinin B2 antagonist S16118–214 (10-5 mol/L), respectively. In each vessel, FMD was assessed before (basal values) and after incubation (20 minutes) with an inhibitor, scavenger, or antagonist. At the end of each experiment, maximal vasodilatation was assessed by the response to sodium nitroprusside (10-4 mol/L) under zero-flow conditions.
Endothelial NO Synthase mRNA Expression
Endothelial NO synthase (eNOS) mRNA expression
was assessed at the level of the gracilis muscle, as described
previously.7
Cardiac Morphometry
Infarct size and cardiac collagen density were assessed using an
image analyzer (Cyberview, Cervus), as described
previously.5
Statistical Analysis
All reported values are given as means±SEM. The responses to
acetylcholine and sodium nitroprusside and the responses to flow are
expressed as a percentage of the reversal of the
phenylephrine-induced constriction. These responses, as
well as the hemodynamic,
echocardiographic, and morphometric
parameters in the sham-operated, untreated CHF, and ACE
inhibitor–treated CHF rats were compared by t
test or by ANOVA followed by a Tukey test for multiple comparisons.
Differences were considered significant at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mortality and Exclusions
A total of 110 rats were included in the study (sham-operated, n=33; untreated, n=44; ACE inhibitor–treated, n=33). During the treatment period, 11 untreated and 3 treated CHF rats died. Furthermore, 13 animals were excluded from the study because of technical difficulties during dissection.
Hemodynamic and Echocardiographic Studies
Table 1
illustrates the
cardiac hemodynamics, CVP, and
echocardiographic parameters measured in
anesthetized animals after 10 weeks of CHF. Compared with
sham-operated animals, CHF decreased LV systolic pressure and
LV dP/dtmax and increased LV
end-diastolic pressure and CVP. ACE inhibition reduced LV
systolic pressure compared with untreated rats and normalized
both LV end-diastolic pressure and CVP without affecting LV
dP/dtmax.
|
Ten weeks after surgery, LV end-diastolic and
systolic diameters were significantly increased in infarcted
animals, and LV fractional shortening was significantly reduced (Table 1
). Simultaneously, both LV posterior wall thickness
and wall thickening were decreased in CHF rats.
Compared with untreated CHF animals, ACE inhibition significantly reduced LV end-diastolic and systolic diameters and increased LV posterior wall thickness. ACE inhibition did not significantly modify LV fractional shortening, but a trend existed toward improved LV posterior wall thickening.
Ten weeks after surgery, cardiac output and stroke volume were significantly reduced in infarcted animals compared with sham-operated rats. Compared with untreated CHF animals, ACE inhibition augmented both cardiac output and stroke volume.
Cardiac Histomorphometry
Table 2 shows the infarct size,
heart weight, body weight, heart weight to body weight ratio, and LV
collagen density in the 3 groups of rats. Infarct size of animals
killed after 10 weeks was identical in untreated and ACE
inhibitor–treated CHF rats (36±3% and 32±2%,
respectively). Compared with sham-operated animals, CHF induced
significant increases in heart weight, heart weight to body weight
ratio, and LV collagen density. ACE inhibition decreased heart weight
and heart weight to body weight ratio, and it normalized LV collagen
density.
|
In Vitro Vascular Studies
The absolute values of arterial diameters at baseline
(ie, before phenylephrine administration) and after
preconstriction by phenylephrine under zero-flow conditions
were similar in the 3 groups (internal diameter after
phenylephrine: 104±5, 105±6, and 108±6 µm in
sham-operated, untreated CHF, and ACE inhibitor–treated
CHF rats, respectively).
Acetylcholine-Mediated Dilatation
Figure 1 illustrates the
responses to acetylcholine obtained in
phenylephrine-constricted femoral arteries from the 3
groups.
|
), untreated CHF rats (•), or ACE inhibitor-treated
CHF rats (
). Results are expressed as mean±SEM.
*P<0.05 vs sham-operated rats; 
P<0.05
vs untreated CHF rats. n=15 in each group.Compared with sham-operated animals, CHF induced a moderate but significant impairment of the vasodilator response to acetylcholine (responses at 10-4 mol/L: 80±2% and 61±3% in sham-operated rats and untreated CHF rats, respectively; P<0.05). ACE inhibition normalized the dilator response to acetylcholine. Indeed, the response to 10-4 mol/L acetylcholine in the arteries isolated from ACE inhibitor–treated CHF rats (81±3%) was identical to that observed in sham animals.
Neither CHF nor ACE inhibition affected the response to the NO donor sodium nitroprusside (data not shown).
FMD
Figure 2 illustrates the changes in
arterial diameter in response to stepwise increases in
intraluminal flow at baseline. In arteries isolated from sham animals,
increases in flow induced a progressive dilatation with a maximum
dilatation of 40±4% at 370 µL/min. CHF abolished FMD and converted
it into vasoconstriction (FMD at 370 mL/min: -4±2%). ACE inhibition
prevented this impairment of FMD (FMD at 370 mL/min: 38±4%).
|
NO and Flow-Mediated Vasodilatation
Figure 3 illustrates the effects of
the NO synthase inhibitor L-NA on FMD in the 3 groups. In
arteries isolated from sham-operated animals, FMD was abolished by
L-NA. Indeed, at the highest value of flow, L-NA reduced FMD from the
basal value of 35±8% to 2±8% (P<0.05). In untreated CHF
rats, FMD was not affected by L-NA (FMD at 370 µL/min before and
after L-NA, -3±3% and 1±2%, respectively). Similar to sham
animals, the FMD of arteries from ACE inhibitor–treated
CHF rats was abolished by L-NA. Indeed, at the highest value of flow
tested, L-NA abolished FMD (2±1%; P<0.05) in arteries
taken from ACE inhibitor–treated animals.
|
Prostaglandins and Flow-Mediated
Vasodilatation
Figure 4 illustrates the effects of
the cyclooxygenase inhibitor diclofenac
on FMD in the 3 groups. In sham-operated animals, FMD was unaffected by
diclofenac (FMD at 370 µL/min before and after diclofenac: 37±10%
and 35±8%, respectively). In contrast, in untreated CHF rats,
diclofenac partially restored flow-induced dilatation (FMD at 370
µL/min before and after diclofenac: -4±2% and 19±5%,
respectively; P<0.05). Similar to sham animals, the FMD of
arteries from ACE inhibitor–treated CHF rats was not
modified (FMD at 370 µL/min before and after diclofenac: 45±10% and
43±11%, respectively; P=NS).
|
Oxygen Free Radicals and Flow-Mediated Vasodilatation
The effects of MPG on FMD are shown in Figure 5. MPG did not affect the responses
obtained in sham-operated rats. In untreated CHF rats, MPG abolished
flow-induced vasoconstriction and re-established a moderate degree of
active vasodilatation (FMD at 370 µL/min before and after MPG:
-8±3% and 6±3%, respectively; P<0.05). Similar to sham
animals, MPG failed to improve FMD in arteries taken from ACE
inhibitor–treated CHF rats (FMD at 370 µL/min before and
after MPG: 36±4% and 37±4%, respectively; P=NS).
|
Bradykinin and Flow-Mediated Vasodilatation
The effects of the bradykinin B2 receptor
antagonist S16118–2 on FMD are shown in Figure 6. S16118–2 did not affect the responses
obtained in sham-operated, untreated, or ACE
inhibitor–treated rats.
|
eNOS mRNA Expression
eNOS mRNA expression was significantly reduced in the rats with
CHF, and this was normalized by ACE inhibition. Indeed, the
eNOS-to-GADPH ratio was 32±3 in sham-operated, 10±4 in
untreated CHF (P<0.05 versus sham), and 30±2 arbitrary
units in ACE inhibitor–treated CHF rats
(P=NS versus sham, P<0.05 versus untreated CHF
rats).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study was performed using the rat model of CHF induced by coronary artery ligation, and it shows that ACE inhibition prevents endothelial dysfunction, as evidenced by restored FMD. This effect of ACE inhibition seems to involve a normalization of NO bioavailability and an abolition of the release and/or the effect of vasoconstrictor prostanoids. In contrast, the stimulation of bradykinin B2 receptors did not seem to be involved in our experimental conditions. Finally, the restoration of NO bioavailability may be partly related to a normalization of eNOS expression, together with a reduced degradation of NO by oxidative stress. To the best of our knowledge, this is the first study in which the effect of long-term ACE inhibition on the FMD of resistance arteries has been studied, although other reports have discussed the effect of acute ACE inhibition on large arteries, especially in humans.15
In a context of severe LV dysfunction, the well-known systemic and cardiac hemodynamic effects of ACE inhibitors were accompanied by a marked effect on endothelium-dependent vascular responses. Indeed, ACE inhibition not only prevented the reduced response to acetylcholine, but it also normalized the FMD of the gracilis artery. The fact that the NO synthase inhibitor L-NA abolished FMD in arteries from ACE inhibitor–treated rats suggests that the normalization of FMD is due, at least in part, to a restoration of the bioavailability of NO. Indeed, the reduced eNOS mRNA expression in CHF animals was completely prevented by ACE inhibition. Although we did not measure the activity or the absolute concentration of the enzyme eNOS, our results support the hypothesis that ACE inhibition prevented the decrease in eNOS.
We can only speculate about the mechanism(s) implicated in the modifications of eNOS RNA expression by ACE inhibitors. One possibility is that the chronic increase in flow, secondary to the peripheral vasodilatory effect of the ACE inhibitor, may by itself be responsible for the increase in eNOS expression. Indeed, an increase in flow induced by an arteriovenous fistula increases endothelium-dependent relaxations to acetylcholine16 and aortic eNOS RNA expression in rats.17 Furthermore, shear stress also enhances eNOS expression and NO release in cultured endothelial cells.18 Alternatively, the exaggerated vasoconstriction induced by CHF at the level of the femoral muscular bed19 may be associated with local muscular tissue hypoxia, which reduces eNOS expression.20 Because of preferential vasodilation of vessels in the muscular territories, ACE inhibitors may prevent local hypoxia and thus indirectly prevent the reduction of eNOS mRNA expression. Again, this suggests that the chronic increase in muscular flow after ACE inhibition is a major contributor to the increased eNOS expression.
ACE inhibition augments eNOS expression and probably also decreases the degradation of NO. Reactive oxygen species are potent inactivators of NO.21 In humans with CHF, an intra-arterial infusion of vitamin C improves the FMD of the brachial artery,8 suggesting increased oxidant stress in this setting. In our experiments, ACE inhibition reduced oxidative stress to a level that did not impair FMD, as illustrated by the fact that MPG had no effect on FMD in ACE inhibitor–treated CHF rats. However, we cannot exclude from the present experiments the possibility that MPG might act by mechanisms other than the scavenging of free radicals. In any case, although we did not measure the amount of free radicals or the oxidative state of the endothelial cells, our data indirectly suggest that ACE inhibition improves FMD partially through decreased oxidative stress.
Several mechanisms may explain the decreased oxidative stress found after ACE inhibition in CHF rats. Indeed, because NO inactivates oxygen-derived free radicals,22 it is possible that the normalized production of NO by ACE inhibition may by itself reduce oxidative stress. Also, it is possible that the changes in oxidant status may be secondary to the changes in flow. Indeed, in cultured endothelial cells, exposure to shear stress increases superoxide dismutase expression and activity.23 Thus, again, it is possible that the chronic increase in tissue flow after ACE inhibition is associated with a maintained or increased antioxidant state in endothelial cells. Alternatively, angiotensin II itself may be a trigger for oxidant stress. Indeed, angiotensin II activates free-radical generating enzymes such as NAPDH oxidase, and this is sufficient to induce severe endothelial dysfunction.24 By reducing local tissue angiotensin II levels, ACE inhibitors could reduce oxidative stress.
Restoration of the NO pathway is not the only mechanism by which ACE inhibition improves endothelial dysfunction. Indeed, in our experimental conditions, the cyclooxygenase inhibitor diclofenac partially restored FMD in arteries from untreated rats, but it had no effect on arteries from ACE inhibitor-treated rats. Thus, in addition to the decreased NO-mediated response, a concomitant production of a vasoconstrictor prostaglandin also contributes to the impaired FMD, and this is probably responsible for the flow-induced vasoconstriction that was observed in CHF rats. A similar increased cyclooxygenase-dependent contraction has also been observed in spontaneously hypertensive rats.25 The fact that the effect of diclofenac was absent in arteries isolated from ACE inhibitor–treated rats suggests that ACE inhibition also prevents the flow-mediated production of vasoconstrictor prostanoids, contributing to the normalization of FMD after ACE inhibition.
Interestingly, the contribution of a cyclooxygenase-dependent vasoconstrictor has been implicated in the alteration of vascular function seen in models of increased oxidant stress, such as the vitamin E–deprived rat.26 27 Moreover, reactive oxygen species activate the COX. Thus, the increased oxidative stress in CHF may, in turn, induce the production of a COX–dependent constricting factor. This mechanism could explain why ACE inhibition prevents the release of both reactive oxygen species and of cyclooxygenase-dependent vasoconstrictors.
In patients with CHF, the contributions of prostaglandins to the regulation of vascular tone and to the interactions between ACE inhibitors and prostaglandins are controversial, especially at the level of the skeletal muscle. Indeed, studies have suggested that aspirin and indomethacin either decrease28 or do not affect29 the response to enalapril on skeletal muscle blood flow. However, another study has shown that prostaglandins contribute to exercise-induced skeletal muscle vasodilatation in patients with CHF.30 The difference between our results and this latter study might be due to the fact that our data were obtained in vitro in the rat femoral artery, and this might markedly differ from the human skeletal vasculature in vivo.
Surprisingly, in our experimental conditions, the bradykinin B2 receptor antagonist S16118–2 did not affect FMD. The vasodilatory effects of bradykinin are not uniform in different species and different vascular beds.31 Thus, the lack of effect of the B2 antagonist in our experiments may be due to the fact that the endogenous production of bradykinin is low in our experimental preparations. Alternatively, peripheral muscular arteries may not express B2 receptors on endothelial cells. This latter hypothesis is supported by the fact that the administration of bradykinin did not induce any vasodilator effect in our vascular preparations, even in the presence of flow and/or chronic ACE inhibition (data not shown).
In conclusion, our study demonstrates that chronic treatment with an ACE inhibitor prevents the CHF-induced impairment of flow-mediated vasodilatation. These beneficial effects are related to an increase in eNOS mRNA expression and are associated with a decreased release of both free radicals and vasoconstrictor prostanoids. The improvement of flow-mediated vasodilatation in small peripheral arteries by ACE inhibitors may contribute to their beneficial effects on exercise capacity in CHF.
Received August 3, 1999; revision received February 3, 2000; accepted February 3, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Zelis R, Hayoz D, Drexler H, et al. Arterial dilatory reserve in congestive heart failure. J Hypertens. 1992;10:S65–S67.
2.
Kubo SH, Rector TS, Bank AJ, et al.
Endothelium-dependent vasodilation is attenuated in
patients with heart failure. Circulation. 1991;84:1589–1596.
3.
Ontkean M, Gay R, Greenberg B. Diminished
endothelium-derived relaxing factor activity in an
experimental of model of chronic heart failure. Circ Res. 1991;69:1088–1096.
4. Teerlink JR, Clozel M, Fischli W, et al. Temporal evolution of endothelial dysfunction in a rat model of chronic heart failure. J Am Coll Cardiol. 1993;22:615–620.[Abstract]
5.
Mulder P, Elfertak L, Richard V, et al.
Peripheral artery structure and endothelial
function in heart failure: effect of ACE inhibition. Am J
Physiol. 1996;271:H469–H474.
6.
Hornig B, Maier V, Drexler H. Physical training
improves endothelial function in patients with chronic
heart failure. Circulation. 1996;93:210–214.
7.
Varin R, Mulder P, Richard V, et al. Chronic exercise
improves flow-dependent dilatation of small muscular arteries in a rat
model of heart failure. Circulation. 1999;99:2951–2957.
8.
Hornig B, Arakawa N, Kohler C, et al. Vitamin C
improves endothelial function of conduit arteries in
patients with chronic heart failure. Circulation. 1998;97:363–368.
9.
Pfeffer JM, Pfeffer MA, Braunwald E. Influence of
chronic captopril therapy on the infarcted left ventricle of the rat.
Circ Res. 1985;57:84–95.
10. Consensus Trial Study. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429–1435.[Abstract]
11.
Pfeffer MA, Pfeffer J, Fishbein M. Myocardial infarct
size and ventricular functions in rats. Circ
Res. 1979;44:503–512.
12.
Mulder P, Richard V, Derumeaux G, et al. Role of
endogenous endothelin in chronic heart failure: effect of a
long term treatment with an endothelin antagonists on
survival, hemodynamics and cardiac remodeling.
Circulation. 1997;96:1976–1982.
13. Halpern W, Kelley M. In vitro methodology for resistance arteries. Blood Vessels. 1991;28:245–251.[Medline] [Order article via Infotrieve]
14.
Feletou M, Lonchampt M, Robineau P, et al. Effects of
the bradykinin B2 receptor antagonist S 16118
(p-guanidobenzoyl-[Hyp3, Thi5, D-Tic7, Oic8]bradykinin) in different
in vivo animal models of inflammation. J Pharmacol Exp
Ther. 1995;273:1078–1084.
15.
Hornig B, Arakawa N, Haussmann D, et al. Differential
effects of quinaprilat and enalaprilat on endothelial
function of conduit arteries in patients with chronic heart failure.
Circulation. 1998;98:2842–2848.
16. Arnal JF, Schott C, Stoclet JC, et al. Vascular relaxation and cyclic guanosine monophosphate in a rat model of high output heart failure. Cardiovasc Res. 1993;27:1651–1656.[Medline] [Order article via Infotrieve]
17.
Nadaud S, Philippe M, Arnal JF, et al. Sustained
increase in aortic endothelial nitric oxide synthase
expression in vivo in a model of chronic high blood flow. Circ
Res. 1996;79:857–863.
18.
Uematsu M, Ohara Y, Navas JP, et al. Regulation of
endothelial cell nitric oxide synthase m RNA expression
by shear stress. Am J Physiol. 1995;269:C1371–C1378.
19.
Musch TI, Tefrell JA. Skeletal muscle blood flow
abnormalities in rats with a chronic myocardial infarction: rest and
exercise. Am J Physiol. 1992;262:H411–H419.
20.
McQuillan LP, Leung GK, Marsden PA, et al.
Hypoxia inhibits expression of eNOS via transcriptional and
posttranscriptional mechanisms. Am J Physiol. 1994;267:H1921–H1927.
21. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature. 1986;320:454–460.[Medline] [Order article via Infotrieve]
22.
Niu XF, Smith W, Kubes P. Intracellular oxidative
stress induced by nitric oxide synthesis inhibition increases
endothelial cell adhesion to neutrophils. Circ
Res. 1994;74:1133–1140.
23.
Inoue N, Ramasamy S, Fukai T, et al. Shear stress
modulates expression of Cu/Zn superoxide dismutase in human aortic
endothelial cells. Circ Res. 1996;79:32–37.
24. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alteration of vasomotor tone. J Clin Invest. 1996;97:1916–1923.[Medline] [Order article via Infotrieve]
25.
Lüscher TF, Vanhoutte PM.
Endothelium-dependent contractions to acetylcholine in
the aorta of the spontaneously hypertensive rats.
Hypertension. 1986;8:344–348.
26. Davidge ST, Hubel CA, McLaughlin MK. Cyclooxygenase-dependent vasoconstrictor alters vascular function in the vitamin E-deprived rat. Circ Res. 1993;73:79–88.[Abstract]
27.
Davidge ST, Ojimba J, McLaughlin MK. Vascular function
in the vitamin E-deprived rat: an interaction between nitric oxide and
superoxide anions. Hypertension. 1998;31:830–835.
28. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1992;20:1549–1555.[Abstract]
29.
Katz SD, Radin M, Graves T, et al. Effect of aspirin
and ifetroban on skeletal muscle blood flow in patients with congestive
heart failure treated with enalapril: Ifetroban Study Group.
J Am Coll Cardiol. 1999;34:170–176.
30.
Lang CC, Chomsky DB, Butler J, et al.
Prostaglandin production contributes to
exercise-induced vasodilation in heart failure. J Appl
Physiol. 1997;83:1933–1940.
31. Mombouli J, Vanhoutte PM. Kinins and endothelium-dependent relaxations to converting enzyme inhibitors in perfused canine arteries. J Cardiovasc Pharmacol. 1991;18:926–927.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  W. Fang, D. G. Oreopoulos, and J. M. Bargman Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3704 - 3710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bouvet, E. B. de Chantemele, A.-L. Guihot, E. Vessieres, A. Bocquet, O. Dumont, A. Jardel, L. Loufrani, P. Moreau, and D. Henrion Flow-Induced Remodeling in Resistance Arteries From Obese Zucker Rats Is Associated With Endothelial Dysfunction Hypertension, July 1, 2007; 50(1): 248 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Li, H. Yin, Y.-Y. Yao, B. Shen, M. Bader, L. Chao, and J. Chao Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3{beta} activation Cardiovasc Res, January 1, 2007; 73(1): 130 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ceconi, K. M. Fox, W. J. Remme, M. L. Simoons, M. Bertrand, G. Parrinello, C. Kluft, A. Blann, D. Cokkinos, and R. Ferrari ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT Cardiovasc Res, January 1, 2007; 73(1): 237 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vercauteren, E. Remy, C. Devaux, B. Dautreaux, J.-P. Henry, F. Bauer, P. Mulder, R. Hooft van Huijsduijnen, A. Bombrun, C. Thuillez, et al. Improvement of Peripheral Endothelial Dysfunction by Protein Tyrosine Phosphatase Inhibitors in Heart Failure Circulation, December 5, 2006; 114(23): 2498 - 2507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Groban and J. Butterworth Perioperative management of chronic heart failure. Anesth. Analg., September 1, 2006; 103(3): 557 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Akishita, K. Nagai, H. Xi, W. Yu, N. Sudoh, T. Watanabe, M. Ohara-Imaizumi, S. Nagamatsu, K. Kozaki, M. Horiuchi, et al. Renin-Angiotensin System Modulates Oxidative Stress-Induced Endothelial Cell Apoptosis in Rats Hypertension, June 1, 2005; 45(6): 1188 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. Chong, A. D. Blann, J. Patel, B. Freestone, E. Hughes, and G. Y.H. Lip Endothelial Dysfunction and Damage in Congestive Heart Failure: Relation of Flow-Mediated Dilation to Circulating Endothelial Cells, Plasma Indexes of Endothelial Damage, and Brain Natriuretic Peptide Circulation, September 28, 2004; 110(13): 1794 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Cox, U. A. Hawkins, B. D. Hoit, and S. C. Tyagi Attenuation of Oxidative Stress and Remodeling by Cardiac Inhibitor of Metalloproteinase Protein Transfer Circulation, May 4, 2004; 109(17): 2123 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schafer, D. Fraccarollo, P. Tas, I. Schmidt, G. Ertl, and J. Bauersachs Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism Eur J Heart Fail, March 1, 2004; 6(2): 151 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Linz, G. Itter, L. W Dobrucki, T. Malinski, and G. Wiemer Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 180 - 185. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Kirima, K. Tsuchiya, H. Sei, T. Hasegawa, M. Shikishima, Y. Motobayashi, K. Morita, M. Yoshizumi, and T. Tamaki Evaluation of systemic blood NO dynamics by EPR spectroscopy: HbNO as an endogenous index of NO Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H589 - H596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schafer, D. Fraccarollo, S. K Hildemann, P. Tas, G. Ertl, and J. Bauersachs Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction Cardiovasc Res, June 1, 2003; 58(3): 655 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ceriello New Insights on Oxidative Stress and Diabetic Complications May Lead to a "Causal" Antioxidant Therapy Diabetes Care, May 1, 2003; 26(5): 1589 - 1596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-Y. Chong, A.D. Blann, and G.Y.H. Lip Assessment of endothelial damage and dysfunction: observations in relation to heart failure QJM, April 1, 2003; 96(4): 253 - 267. [Full Text] [PDF]
|
|
|
|
 |
|
 F. N. Witherow, P. Dawson, C. A. Ludlam, K. A. A. Fox, and D. E. Newby Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy J. Am. Coll. Cardiol., September 4, 2002; 40(5): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mukai, H. Shimokawa, M. Higashi, K. Morikawa, T. Matoba, J. Hiroki, I. Kunihiro, H. M.A. Talukder, and A. Takeshita Inhibition of Renin-Angiotensin System Ameliorates Endothelial Dysfunction Associated With Aging in Rats Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1445 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Murakami, K. Mizushige, T. Noma, T. Tsuji, S. Kimura, and M. Kohno Perindopril Effect on Uncoupling Protein and Energy Metabolism in Failing Rat Hearts Hypertension, September 1, 2002; 40(3): 251 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hunt, G. M. Aru, M. R. Hayden, C. K. Moore, B. D. Hoit, and S. C. Tyagi Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure Am J Physiol Lung Cell Mol Physiol, August 1, 2002; 283(2): L239 - L245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Ellis, A. K. Nightingale, D. J. Blackman, R. A. Anderson, C. Mumford, G. Timmins, D. Lang, S. K. Jackson, M. D. Penney, M. J. Lewis, et al. Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress Eur J Heart Fail, March 1, 2002; 4(2): 193 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Zhou, A. Adam, and L. Raij Review: Interaction among angiotensin II, nitric oxide and oxidative stress Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S59 - S63. [PDF]
|
|
|
|
|
|
M. J. Cox, H. S. Sood, M. J. Hunt, D. Chandler, J. R. Henegar, G. M. Aru, and S. C. Tyagi Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1197 - H1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Loot, A. J.M. Roks, R. H. Henning, R. A. Tio, A. J.H. Suurmeijer, F. Boomsma, and W. H. van Gilst Angiotensin-(1-7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats Circulation, April 2, 2002; 105(13): 1548 - 1550. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||